No Data
No Data
Buy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth Potential
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)
Decoding 6 Analyst Evaluations For Xencor
6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below offers a condensed view of their r
Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
Xencor Is Maintained at Outperform by Wedbush
Xencor Is Maintained at Outperform by Wedbush
Xencor Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 54.57% Wedbush $34 → $36 Maintains Outperform 04/16/2024 63.16% BTIG $56 → $38 Maintains Buy 02
No Data